课题基金 / 基金详情

Novel biomarker analysis predicting efficacy of immune checkpoint inhibitors

Novel biomarker analysis predicting efficacy of immune checkpoint inhibitors
预测免疫检查点抑制剂功效的新型生物标志物分析
批准号:
16K10687
负责人:
SUZUKI HIROYUKI
金额:
$2.91万
依托单位国家:
日本
项目类别:
Grant-in-Aid for Scientific Research (C)
财政年份:
2016
资助国家:
日本
项目状态:
已结题
起止时间:
2016-04-01 至 2019-03-31

项目摘要

项目成果

SUZUKI HIROYUKI的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
DOI: 10.1159/000443662
发表时间: 2016-01
期刊: Case reports in oncology
影响因子: 0.8
作者: [Osugi J, Owada Y, Yamaura T, Muto S, Okabe N, Matsumura Y, Higuchi M, Suzuki H, Gotoh M]
通讯作者: Gotoh M
Family with sequence similarity 83, member B is a predictor of poor prognosis and a potential therapeutic target for lung adenocarcinoma expressing wild-type epidermal growth factor receptor.
具有序列相似性的家族83,成员B是预后不良的预测指标,也是表达野生型表皮生长因子受体的肺腺癌的潜在治疗靶标。
DOI: 10.3892/ol.2017.7517
发表时间: 2018-03
期刊: Oncology letters
影响因子: 2.9
作者: [Yamaura T, Ezaki J, Okabe N, Takagi H, Ozaki Y, Inoue T, Watanabe Y, Fukuhara M, Muto S, Matsumura Y, Hasegawa T, Hoshino M, Osugi J, Shio Y, Waguri S, Tamura H, Imai JI, Ito E, Yanagisawa Y, Honma R, Watanabe S, Suzuki H]
通讯作者: Suzuki H
Predicting outcomes of advanced non-small cell lung cancer patients treated with PD-1/PDL-1 inhibitors: Independent international validation of the iSEND model.
预测接受 PD-1/PDL-1 抑制剂治疗的晚期非小细胞肺癌患者的结果:iSEND 模型的独立国际验证。
DOI: --
发表时间: 2018
期刊:
影响因子: --
作者: [Wungki Park, Laura Mezquita, Naoyuki Okabe, Deukwoo Kwon, Diana Saravia, Young Kwang Chae, Amrita Desai, David Planchard, Caroline Caramella, Raja Mudad, Mohammad Jahanzeb, Hiroyuki Suzuki, Benjamin Besse, Gilberto Lopes.]
通讯作者: Gilberto Lopes.
Comprehensive genomic analysis with immunological parameters to obtain the biomarkers for immune checkpoint inhibitors (ICIs) in Non-Small Cell Lung Cancer (NSCLC)
使用免疫学参数进行全面的基因组分析,以获得非小细胞肺癌 (NSCLC) 中免疫检查点抑制剂 (ICIs) 的生物标志物
DOI: --
发表时间: 2017
期刊:
影响因子: --
作者: [Yuki Owada, Satoshi Muto, Hironori Takagi, Takuya Inoue, Yuzuru Watanabe, Takumi Yamaura, Mitsuro Fukuhara, Naoyuki Okabe, Yuki Matsumura, Takeo Hasegawa, Daisuke Tanaka, Emi Ito, Hideaki Nanamiya, Jun-ichi Imai, Takao Isogai, Shinya Watanabe, Hiroyuki Su]
通讯作者: Hiroyuki Su
52
    Novel immunotherapy targeting to Neo-antigen specific T cell for lung cancer
    • 批准号:
      19K09310
    • 项目类别:
      Grant-in-Aid for Scientific Research (C)
    • 资助金额:
      $2.75万
    • 财政年份:
      2019
    • 负责人:
      SUZUKI HIROYUKI
    • 依托单位:
    The control of FGFR signal by heparan sulfate chain degrading enzyme results in altered closure of cranial suture in Apert mouse model
    • 批准号:
      26861777
    • 项目类别:
      Grant-in-Aid for Young Scientists (B)
    • 资助金额:
      $2.41万
    • 财政年份:
      2014
    • 负责人:
      SUZUKI HIROYUKI
    • 依托单位:
    Clarify of chemo-resistant mechanism in lung cancer targeting to epigenetic aberration
    • 批准号:
      25462182
    • 项目类别:
      Grant-in-Aid for Scientific Research (C)
    • 资助金额:
      $3.08万
    • 财政年份:
      2013
    • 负责人:
      SUZUKI HIROYUKI
    • 依托单位:
    Physiological Significance of Redistribution of Intermediate Filaments in the Mammalian Oocytes and Its Signal Transduction Pathways
    • 批准号:
      24580403
    • 项目类别:
      Grant-in-Aid for Scientific Research (C)
    • 资助金额:
      $3.0万
    • 财政年份:
      2012
    • 负责人:
      SUZUKI HIROYUKI
    • 依托单位:
    海外基金